Pharsight

Moxeza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450311 NOVARTIS Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
May, 2029

(5 years from now)

US9114168 NOVARTIS Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
May, 2029

(5 years from now)

Moxeza is owned by Novartis.

Moxeza contains Moxifloxacin Hydrochloride.

Moxeza has a total of 2 drug patents out of which 0 drug patents have expired.

Moxeza was authorised for market use on 19 November, 2010.

Moxeza is available in solution/drops;ophthalmic dosage forms.

The generics of Moxeza are possible to be released after 29 May, 2029.

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 19 November, 2010

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of MOXEZA before it's drug patent expiration?
More Information on Dosage

MOXEZA family patents

Family Patents